Viatris Inc vs Zillow Group Inc Class C — how do they compare? Viatris Inc trades at $17.64 (market cap $20.03B), while Zillow Group Inc Class C trades at $29.01 (market cap $6.59B). The key difference: Viatris Inc is far larger — about 3× Zillow Group Inc Class C's market cap, and Viatris Inc pays a 2.75% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Zillow Group Inc Class C for 38 Days on average.
| VTRS | Z | |
|---|---|---|
Market Cap | $20.03B | $6.59B |
Volume | 14,109,977 | 9,134,294 |
Sector | Health | Media |
52-Week High | $18.27 | $78.04 |
52-Week Low | $9.74 | $27.13 |
Typical Hold Time | 57 Days | 38 Days |
Enterprise Value | $32.15B | $6.47B |
Dividend Yield | 2.75% | — |
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Zillow Group (Z) trades at $29.01, up 6.34% in the past 24 hours, showing strong momentum despite mixed technical signals. The company demonstrates improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability with $23M net income. Recent earnings show two consecutive beats against expectations, though the stock faces headwinds from elevated mortgage rates and housing market volatility.
The outlook remains cautiously optimistic with analyst consensus price target of $60.33 suggesting significant upside potential. However, investors face risks from housing market sensitivity to interest rates and competitive pressures. The company's transition to an integrated transaction platform and AI integration present growth opportunities, but execution risks and market conditions warrant careful monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →